Merck announced the results from its Phase 3 study of its investigational Ambrosia artemisiifolia (ragweed) allergy immunotherapy tablet (AIT) for ragweed pollen allergy.
The 52-week, multicenter, double-blind, randomized, placebo-controlled, parallel-group was conducted in 565 adults who were 18–50 years old with ragweed-induced allergic rhinoconjunctivitis, with or without asthma. The majority of these patients (85%) were sensitive to multiple allergens. Study results showed that the use of ragweed AIT significantly reduced the total combined score that measured nasal and eye symptoms and use of rescue allergy medicines, compared to placebo, in ragweed-allergic adults with or without asthma. The study was conducted during peak ragweed pollen season.
AIT is an investigational, dissolvable oral tablet designed to treat the underlying cause of allergies, and is being studied to determine whether AIT may help to prevent allergy symptoms by generating an immune response to protect against targeted allergens. Merck is investigating disease-modifying AITs for the treatment of allergies caused by ragweed pollen, grass pollen and house dust mites.
For more information call (800) 672-6372 or visit www.merck.com.